During the last session, 60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP)’s traded shares were 65702.0, with the beta value of the company hitting 1.25. At the end of the trading day, the stock’s price was $3.16, reflecting an intraday loss of -0.32% or -$0.01. The 52-week high for the SXTP share is $35.99, that puts it down -1038.92 from that peak though still a striking 55.38% gain since the share price plummeted to a 52-week low of $1.41. The company’s market capitalization is $4.66M, and the average intraday trading volume over the past 10 days was 9.22 million shares, and the average trade volume was 1.89 million shares over the past three months.
60 Degrees Pharmaceuticals Inc (SXTP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. SXTP has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.32.
60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP) trade information
60 Degrees Pharmaceuticals Inc (SXTP) registered a -0.32% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.32% in intraday trading to $3.16, hitting a weekly high. The stock’s 5-day price performance is 1.94%, and it has moved by 58.79% in 30 days. Based on these gigs, the overall price performance for the year is -79.74%. The short interest in 60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP) is 29231.0 shares and it means that shorts have 0.8 day(s) to cover.
60 Degrees Pharmaceuticals Inc (SXTP) estimates and forecasts
In the rating firms’ projections, revenue will increase 165.24% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 301k as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 376.5k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 116.46k and 124.97k respectively. In this case, analysts expect current quarter sales to grow by 158.46% and then jump by 201.27% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 12.29%. While earnings are projected to return 81.77% in 2025, the next five years will return 71.59% per annum.
SXTP Dividends
60 Degrees Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-Mar-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP)’s Major holders
60 Degrees Pharmaceuticals Inc insiders own 4.33% of total outstanding shares while institutional holders control 2.09%, with the float percentage being 2.18%.
Also, the Mutual Funds coming in first place with the largest holdings of 60 Degrees Pharmaceuticals Inc (SXTP) shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund . Data provided on Feb 28, 2025 indicates that Fidelity Concord Street Trust-Fidelity Extended Market Index Fund owns about 775.0 shares. This amounts to just over 0.05 percent of the company’s overall shares, with a $2449.0 market value. The same data shows that the other fund manager holds slightly less at 427.0, or about 0.03% of the stock, which is worth about $1349.0.
